Impact Therapeutics (HKG:7630) presented the latest clinical data for its pipeline drugs Senaparib, IMP1734, and IMP1707 as posters at the 2026 European Society for Medical Oncology (ESMO) Congress.
The data included the first-line maintenance benefit of Senaparib in advanced ovarian cancer, a Friday bourse filing showed.
The results of IMP1734 and IMP1707 for the treatment of advanced solid tumors also showed favorable safety profiles.
The ESMO Congress took place in Madrid, Spain, from Oct. 23 to 27.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments